Skip to Content
Merck
All Photos(1)

Key Documents

569427-U

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 12.5 cm × 4.6 mm, HPLC Column

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 12.5 cm × 4.6 mm

material

stainless steel column

Quality Level

Agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

12.5 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Features and Benefits

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of

Related Content

Discovery C18 and C8 HPLC Columns products offered

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service